51
|
Toome K, Willmore AMA, Paiste P, Tobi A, Sugahara KN, Kirsimäe K, Ruoslahti E, Braun GB, Teesalu T. Ratiometric in vivo auditioning of targeted silver nanoparticles. NANOSCALE 2017; 9:10094-10100. [PMID: 28695222 PMCID: PMC5687556 DOI: 10.1039/c7nr04056c] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/07/2023]
Abstract
Attaching affinity ligands to nanoparticles (NPs) increases selectivity for targeting cells and tissues, and can result in improved sensitivity and reduced off-target toxicity in diagnostic and therapeutic systems. The decision over key features - NP size, shape, coating strategies and targeting ligands for clinical translation is often hampered by a lack of quantitative in vivo NP homing assays. Sensitive, internally controlled assays are needed which allow for quantitative comparisons (auditions) among various formulations of targeted NPs. We recently reported the development of peptide-functionalized, isotopically-barcoded silver NPs (AgNPs) for ultrasensitive studies centered on measuring relative ratios of NP internalization into cultured cells. Here we evaluated the application of this technology for NP homing studies in live mice using peptides with previously described tissue tropism; one peptide that favors vascular beds of the normal lungs (RPARPAR; receptor neuropilin-1, or NRP-1) and another that is selective for central nervous system vessels (CAGALCY). Equimolar mixtures of the peptide-targeted Ag107-NPs and Ag109 control particles were mixed and injected intravenously. Distribution profiles of Ag107 and Ag109 in tissue extracts were determined simultaneously through inductively coupled plasma mass spectrometry (ICP-MS). Compared to non-targeted particles up to ∼9-fold increased lung accumulation was seen for RPARPAR-OH AgNPs (but not for AgNPs functionalized with RPARPAR-NH2, which does not bind to NRP-1). Similarly, AgNPs functionalized with the brain-homing CAGALCY peptide were overrepresented in brain extracts. Spatial distribution (mapping) analysis by laser ablation ICP-MS (LA-ICP-MS) was used to determine the ratio Ag107/Ag109 in tissue cryosections. The mapping demonstrated preferential accumulation of the RPARPAR-AgNPs in the perivascular areas around pulmonary veins, and CAGALCY AgNPs accumulated in discrete areas of the brain (e.g. in the vessels of cerebellar fibrillary tracts). Based on these results, the internally controlled ratiometric AgNP system is suitable for quantitative studies of the effect of targeting ligands on NP biodistribution, at average tissue concentration and distribution at the microscopic level. The platform might be particularly relevant for target sites with high local variability in uptake, such as tumors.
Collapse
Affiliation(s)
- Kadri Toome
- Laboratory of Cancer Biology, Institute of Biomedicine and Translational Medicine, University of Tartu, Ravila 14B, Tartu, 50411, Estonia
| | - Anne-Mari A. Willmore
- Laboratory of Cancer Biology, Institute of Biomedicine and Translational Medicine, University of Tartu, Ravila 14B, Tartu, 50411, Estonia
| | - Päärn Paiste
- Department of Geology, University of Tartu, Ravila 14A, Tartu, 50411, Estonia
| | - Allan Tobi
- Laboratory of Cancer Biology, Institute of Biomedicine and Translational Medicine, University of Tartu, Ravila 14B, Tartu, 50411, Estonia
| | - Kazuki N. Sugahara
- Department of Surgery, Columbia University College of Physicians and Surgeons, New York, New York, USA
- Cancer Research Center, Sanford Burnham Prebys Medical Discovery Institute, 10901 N. Torrey Pines Road, La Jolla, 92097 California, USA
| | - Kalle Kirsimäe
- Department of Geology, University of Tartu, Ravila 14A, Tartu, 50411, Estonia
| | - Erkki Ruoslahti
- Cancer Research Center, Sanford Burnham Prebys Medical Discovery Institute, 10901 N. Torrey Pines Road, La Jolla, 92097 California, USA
- Center for Nanomedicine and Department of Cell, Molecular and Developmental Biology, University of California, Santa Barbara, 93106 California, USA
| | - Gary B. Braun
- Cancer Research Center, Sanford Burnham Prebys Medical Discovery Institute, 10901 N. Torrey Pines Road, La Jolla, 92097 California, USA
| | - Tambet Teesalu
- Laboratory of Cancer Biology, Institute of Biomedicine and Translational Medicine, University of Tartu, Ravila 14B, Tartu, 50411, Estonia
- Cancer Research Center, Sanford Burnham Prebys Medical Discovery Institute, 10901 N. Torrey Pines Road, La Jolla, 92097 California, USA
- Center for Nanomedicine and Department of Cell, Molecular and Developmental Biology, University of California, Santa Barbara, 93106 California, USA
| |
Collapse
|
52
|
Role of carbonic anhydrases in skin wound healing. Exp Mol Med 2017; 49:e334. [PMID: 28524177 PMCID: PMC5454449 DOI: 10.1038/emm.2017.60] [Citation(s) in RCA: 24] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/23/2016] [Revised: 12/07/2016] [Accepted: 12/09/2016] [Indexed: 02/08/2023] Open
Abstract
Skin wound closure occurs when keratinocytes migrate from the edge of the wound and re-epithelialize the epidermis. Their migration takes place primarily before any vascularization is established, that is, under hypoxia, but relatively little is known regarding the factors that stimulate this migration. Hypoxia and an acidic environment are well-established stimuli for cancer cell migration. The carbonic anhydrases (CAs) contribute to tumor cell migration by generating an acidic environment through the conversion of carbon dioxide to bicarbonate and a proton. On this basis, we explored the possible role of CAs in tissue regeneration using mouse skin wound models. We show that the expression of mRNAs encoding CA isoforms IV and IX are increased (~25 × and 4 ×, respectively) during the wound hypoxic period (days 2-5) and that cells expressing CAs form a band-like structure beneath the migrating epidermis. RNA-Seq analysis suggested that the CA IV-specific signal in the wound is mainly derived from neutrophils. Due to the high level of induction of CA IV in the wound, we treated skin wounds locally with recombinant human CA IV enzyme. Recombinant CA IV significantly accelerated wound re-epithelialization. Thus, CA IV could contribute to wound healing by providing an acidic environment in which the migrating epidermis and neutrophils can survive and may offer novel opportunities to accelerate wound healing under compromised conditions.
Collapse
|
53
|
Järvinen TAH, Rashid J, Valmari T, May U, Ahsan F. Systemically Administered, Target-Specific Therapeutic Recombinant Proteins and Nanoparticles for Regenerative Medicine. ACS Biomater Sci Eng 2017; 3:1273-1282. [DOI: 10.1021/acsbiomaterials.6b00746] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Affiliation(s)
- Tero A. H. Järvinen
- Faculty
of Medicine and Life Sciences, University of Tampere, Lääkärinkatu
1, 33014 Tampere, Finland
- Department of Orthopedics & Traumatology, Tampere University Hospital, Teiskontie 35, 33520 Tampere, Finland
| | - Jahidur Rashid
- Department
of Pharmaceutical Sciences, School of Pharmacy, Texas Tech University Health Sciences Center, 1300 Coulter Street, Amarillo, Texas 79106, United States
| | - Toini Valmari
- Faculty
of Medicine and Life Sciences, University of Tampere, Lääkärinkatu
1, 33014 Tampere, Finland
| | - Ulrike May
- Faculty
of Medicine and Life Sciences, University of Tampere, Lääkärinkatu
1, 33014 Tampere, Finland
| | - Fakhrul Ahsan
- Department
of Pharmaceutical Sciences, School of Pharmacy, Texas Tech University Health Sciences Center, 1300 Coulter Street, Amarillo, Texas 79106, United States
| |
Collapse
|
54
|
Thu VT, Kim HK, Long LT, Thuy TT, Huy NQ, Kim SH, Kim N, Ko KS, Rhee BD, Han J. NecroX-5 exerts anti-inflammatory and anti-fibrotic effects via modulation of the TNFα/Dcn/TGFβ1/Smad2 pathway in hypoxia/reoxygenation-treated rat hearts. THE KOREAN JOURNAL OF PHYSIOLOGY & PHARMACOLOGY : OFFICIAL JOURNAL OF THE KOREAN PHYSIOLOGICAL SOCIETY AND THE KOREAN SOCIETY OF PHARMACOLOGY 2016; 20:305-14. [PMID: 27162485 PMCID: PMC4860373 DOI: 10.4196/kjpp.2016.20.3.305] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 02/26/2016] [Revised: 03/04/2016] [Accepted: 03/04/2016] [Indexed: 12/12/2022]
Abstract
Inflammatory and fibrotic responses are accelerated during the reperfusion period, and excessive fibrosis and inflammation contribute to cardiac malfunction. NecroX compounds have been shown to protect the liver and heart from ischemia-reperfusion injury. The aim of this study was to further define the role and mechanism of action of NecroX-5 in regulating infl ammation and fi brosis responses in a model of hypoxia/reoxygenation (HR). We utilized HR-treated rat hearts and lipopolysaccharide (LPS)-treated H9C2 culture cells in the presence or absence of NecroX-5 (10 µmol/L) treatment as experimental models. Addition of NecroX-5 signifi cantly increased decorin (Dcn) expression levels in HR-treated hearts. In contrast, expression of transforming growth factor beta 1 (TGFβ1) and Smad2 phosphorylation (pSmad2) was strongly attenuated in NecroX-5-treated hearts. In addition, signifi cantly increased production of tumor necrosis factor alpha (TNFα), TGFβ1, and pSmad2, and markedly decreased Dcn expression levels, were observed in LPS-stimulated H9C2 cells. Interestingly, NecroX-5 supplementation effectively attenuated the increased expression levels of TNFα, TGFβ1, and pSmad2, as well as the decreased expression of Dcn. Thus, our data demonstrate potential antiinflammatory and anti-fibrotic effects of NecroX-5 against cardiac HR injuries via modulation of the TNFα/Dcn/TGFβ1/Smad2 pathway.
Collapse
Affiliation(s)
- Vu Thi Thu
- National Research Laboratory for Mitochondrial Signaling, Department of Physiology, Department of Health Sciences and Technology, BK21 Project Team, College of Medicine, Cardiovascular and Metabolic Disease Center, Inje University, Busan 47392, Korea.; VNU University of Science, Hanoi 120036, Vietnam
| | - Hyoung Kyu Kim
- National Research Laboratory for Mitochondrial Signaling, Department of Physiology, Department of Health Sciences and Technology, BK21 Project Team, College of Medicine, Cardiovascular and Metabolic Disease Center, Inje University, Busan 47392, Korea.; Department of Integrated Biomedical Science, College of Medicine, Inje University, Busan 47392, Korea
| | - Le Thanh Long
- National Research Laboratory for Mitochondrial Signaling, Department of Physiology, Department of Health Sciences and Technology, BK21 Project Team, College of Medicine, Cardiovascular and Metabolic Disease Center, Inje University, Busan 47392, Korea
| | | | | | - Soon Ha Kim
- Product Strategy and Development, LG Life Sciences Ltd., Seoul 03184, Korea
| | - Nari Kim
- National Research Laboratory for Mitochondrial Signaling, Department of Physiology, Department of Health Sciences and Technology, BK21 Project Team, College of Medicine, Cardiovascular and Metabolic Disease Center, Inje University, Busan 47392, Korea
| | - Kyung Soo Ko
- National Research Laboratory for Mitochondrial Signaling, Department of Physiology, Department of Health Sciences and Technology, BK21 Project Team, College of Medicine, Cardiovascular and Metabolic Disease Center, Inje University, Busan 47392, Korea
| | - Byoung Doo Rhee
- National Research Laboratory for Mitochondrial Signaling, Department of Physiology, Department of Health Sciences and Technology, BK21 Project Team, College of Medicine, Cardiovascular and Metabolic Disease Center, Inje University, Busan 47392, Korea
| | - Jin Han
- National Research Laboratory for Mitochondrial Signaling, Department of Physiology, Department of Health Sciences and Technology, BK21 Project Team, College of Medicine, Cardiovascular and Metabolic Disease Center, Inje University, Busan 47392, Korea
| |
Collapse
|
55
|
Liposomal Aerosols of Nitric Oxide (NO) Donor as a Long-Acting Substitute for the Ultra-Short-Acting Inhaled NO in the Treatment of PAH. Pharm Res 2016; 33:1696-710. [PMID: 27048347 DOI: 10.1007/s11095-016-1911-7] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/13/2016] [Accepted: 03/17/2016] [Indexed: 01/12/2023]
Abstract
PURPOSE This study seeks to develop a liposomal formulation of diethylenetriamine NONOate (DN), a long acting nitric oxide (NO) donor, with a goal to replace inhaled NO (iNO) in the treatment of pulmonary arterial hypertension (PAH). METHODS Liposomal formulations were prepared by a lipid film hydration method and modified with a cell penetrating peptide, CAR. The particles were characterized for size, polydispersity index (PDI), zeta potential, entrapment efficiency, storage and nebulization stability, and in-vitro release profiles. The cellular uptake and transport were assessed in rat alveolar macrophages (NR8383) and transforming growth factor β (TGF-β) activated rat pulmonary arterial smooth muscle cells (PASMCs). The fraction of the formulation that enters the systemic circulation, after intratracheal administration, was determined in an Isolated Perfused Rat Lung (IPRL) model. The safety of the formulations were assessed using an MTT assay and by measuring injury markers in the bronchoalveolar lavage (BAL) fluid; the pharmacological efficacy was evaluated by monitoring the changes in the mean pulmonary arterial (mPAP) and systemic pressure (mSAP) in a monocrotaline (MCT) induced-PAH rat model RESULTS Liposome size, zeta potential, and entrapment efficiency were 171 ± 4 nm, -37 ± 3 mV, and 46 ± 5%, respectively. The liposomes released 70 ± 5% of the drug in 8 h and were stable when stored at 4°C. CAR-conjugated-liposomes were taken up more efficiently by PASMCs than liposomes-without-CAR; the uptake of the formulations by rat alveolar macrophages was minimal. DN-liposomes did not increase lung weight, protein quantity, and levels of injury markers in the BAL fluid. Intratracheal CAR-liposomes reduced the entry of liposomes from the lung to blood; the formulations produced a 40% reduction in mPAP for 180 minutes. CONCLUSION This study establishes the proof-of-concept that peptide modified liposomal formulations of long-acting NO donor can be an alternative to short-acting iNO.
Collapse
|
56
|
Lichtman MK, Otero-Vinas M, Falanga V. Transforming growth factor beta (TGF-β) isoforms in wound healing and fibrosis. Wound Repair Regen 2016; 24:215-22. [PMID: 26704519 DOI: 10.1111/wrr.12398] [Citation(s) in RCA: 353] [Impact Index Per Article: 44.1] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/03/2015] [Revised: 11/19/2015] [Accepted: 12/22/2015] [Indexed: 12/12/2022]
Abstract
Scar formation, with persistent alteration of the normal tissue structure, is an undesirable and significant result of both wound healing and fibrosing disorders. There are few strategies to prevent or to treat scarring. The transforming growth factor beta (TGF-β) superfamily is an important mediator of tissue repair. Each TGF-β isoform may exert a different effect on wound healing, which may be context-dependent. In particular, TGF-β1 may mediate fibrosis in adults' wounds, while TGF-β3 may promote scarless healing in the fetus and reduced scarring in adults. Thus, TGF-β3 may offer a scar-reducing therapy for acute and chronic wounds and fibrosing disorders.
Collapse
Affiliation(s)
- Michael K Lichtman
- Department of Dermatology, Boston University School of Medicine, Boston, Massachusetts.,Veterans' Administration, Boston Healthcare System, Division of Dermatology, Boston University School of Medicine, Boston, Massachusetts
| | - Marta Otero-Vinas
- Department of Dermatology, Boston University School of Medicine, Boston, Massachusetts.,Department of Systems Biology, The Tissue Repair and Regeneration Laboratory, University of Vic-Central University of Catalonia, Vic, Spain
| | - Vincent Falanga
- Department of Dermatology, Boston University School of Medicine, Boston, Massachusetts.,Department of Biochemistry, Boston University School of Medicine, Boston, Massachusetts
| |
Collapse
|
57
|
Scodeller P. Extracellular Matrix Degrading Enzymes for Nanocarrier-Based Anticancer Therapy. INTRACELLULAR DELIVERY III 2016. [DOI: 10.1007/978-3-319-43525-1_3] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
|
58
|
Decorin: A Growth Factor Antagonist for Tumor Growth Inhibition. BIOMED RESEARCH INTERNATIONAL 2015; 2015:654765. [PMID: 26697491 PMCID: PMC4677162 DOI: 10.1155/2015/654765] [Citation(s) in RCA: 71] [Impact Index Per Article: 7.9] [Reference Citation Analysis] [Abstract] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 07/27/2015] [Accepted: 10/21/2015] [Indexed: 01/12/2023]
Abstract
Decorin (DCN) is the best characterized member of the extracellular small leucine-rich proteoglycan family present in connective tissues, typically in association with or “decorating” collagen fibrils. It has substantial interest to clinical medicine owing to its antifibrotic, anti-inflammatory, and anticancer effects. Studies on DCN knockout mice have established that a lack of DCN is permissive for tumor development and it is regarded as a tumor suppressor gene. A reduced expression or a total disappearance of DCN has been reported to take place in various forms of human cancers during tumor progression. Furthermore, when used as a therapeutic molecule, DCN has been shown to inhibit tumor progression and metastases in experimental cancer models. DCN affects the biology of various types of cancer by targeting a number of crucial signaling molecules involved in cell growth, survival, metastasis, and angiogenesis. The active sites for the neutralization of different growth factors all reside in different parts of the DCN molecule. An emerging concept that multiple proteases, especially those produced by inflammatory cells, are capable of cleaving DCN suggests that native DCN could be inactivated in a number of pathological inflammatory conditions. In this paper, we review the role of DCN in cancer.
Collapse
|
59
|
Järvinen TAH, May U, Prince S. Systemically Administered, Target Organ-Specific Therapies for Regenerative Medicine. Int J Mol Sci 2015; 16:23556-71. [PMID: 26437400 PMCID: PMC4632713 DOI: 10.3390/ijms161023556] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/31/2015] [Revised: 09/17/2015] [Accepted: 09/22/2015] [Indexed: 12/12/2022] Open
Abstract
Growth factors and other agents that could potentially enhance tissue regeneration have been identified, but their therapeutic value in clinical medicine has been limited for reasons such as difficulty to maintain bioactivity of locally applied therapeutics in the protease-rich environment of regenerating tissues. Although human diseases are treated with systemically administered drugs in general, all current efforts aimed at enhancing tissue repair with biological drugs have been based on their local application. The systemic administration of growth factors has been ruled out due to concerns about their safety. These concerns are warranted. In addition, only a small proportion of systemically administered drugs reach their intended target. Selective delivery of the drug to the target tissue and use of functional protein domains capable of penetrating cells and tissues could alleviate these problems in certain circumstances. We will present in this review a novel approach utilizing unique molecular fingerprints (“Zip/postal codes”) in the vasculature of regenerating tissues that allows target organ-specific delivery of systemically administered therapeutic molecules by affinity-based physical targeting (using peptides or antibodies as an “address tag”) to injured tissues undergoing repair. The desired outcome of targeted therapies is increased local accumulation and lower systemic concentration of the therapeutic payload. We believe that the physical targeting of systemically administered therapeutic molecules could be rapidly adapted in the field of regenerative medicine.
Collapse
Affiliation(s)
- Tero A H Järvinen
- School of Medicine, University of Tampere, 33520 Tampere, Finland.
- Department of Orthopedics & Traumatology, Tampere University Hospital, 33520 Tampere, Finland.
| | - Ulrike May
- School of Medicine, University of Tampere, 33520 Tampere, Finland.
| | - Stuart Prince
- School of Medicine, University of Tampere, 33520 Tampere, Finland.
| |
Collapse
|
60
|
Resistance of R-Ras knockout mice to skin tumour induction. Sci Rep 2015; 5:11663. [PMID: 26133397 PMCID: PMC4488886 DOI: 10.1038/srep11663] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/22/2014] [Accepted: 06/01/2015] [Indexed: 12/14/2022] Open
Abstract
The R-ras gene encodes a small GTPase that is a member of the Ras family. Despite close sequence similarities, R-Ras is functionally distinct from the prototypic Ras proteins; no transformative activity and no activating mutations of R-Ras in human malignancies have been reported for it. R-Ras activity appears inhibitory towards tumour proliferation and invasion, and to promote cellular quiescence. Contrary to this, using mice with a deletion of the R-ras gene, we found that R-Ras facilitates DMBA/TPA-induced skin tumour induction. The tumours appeared in wild-type (WT) mice on average 6 weeks earlier than in R-Ras knockout (R-Ras KO) mice. WT mice developed almost 6 times more tumours than R-Ras KO mice. Despite strong R-Ras protein expression in the dermal blood vessels, no R-Ras could be detected in the epidermis from where the tumours arose. The DMBA/TPA skin tumourigenesis-model is highly dependent upon inflammation, and we found a greatly attenuated skin inflammatory response to DMBA/TPA-treatment in the R-Ras KO mice in the context of leukocyte infiltration and proinflammatory cytokine expression. Thus, these data suggest that despite its characterised role in promoting cellular quiescence, R-Ras is pro-tumourigenic in the DMBA/TPA tumour model and important for the inflammatory response to DMBA/TPA treatment.
Collapse
|
61
|
Lee WJ, Ahn HM, Roh H, Na Y, Choi IK, Lee JH, Kim YO, Lew DH, Yun CO. Decorin-expressing adenovirus decreases collagen synthesis and upregulates MMP expression in keloid fibroblasts and keloid spheroids. Exp Dermatol 2015; 24:591-7. [PMID: 25865370 DOI: 10.1111/exd.12719] [Citation(s) in RCA: 28] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 04/08/2015] [Indexed: 02/06/2023]
Abstract
Decorin is a natural transforming growth factor-β1 (TGF-β1) antagonist. Reduced decorin synthesis is associated with dermal scarring, and increased decorin expression appears to reduce scar tissue formation. To investigate the therapeutic potential of decorin for keloids, human dermal fibroblasts (HDFs) and keloid-derived fibroblasts (KFs) were transduced with decorin-expressing adenovirus (dE1-RGD/GFP/DCN), and we examined the therapeutic potential of decorin-expressing Ad for treating pathologic skin fibrosis. Decorin expression was examined by immunofluorescence assay on keloid tissues. HDFs and KFs were transduced with dE1-RGD/GFP/DCN or control virus, and protein levels of decorin, epidermal growth factor receptor (EGFR) and secreted TGF-β1 were assessed by Western blotting and ELISA. And type I and III collagen, and matrix metalloproteinase-1 (MMP-1) and matrix metalloproteinase-3 (MMP-3) mRNA levels were measured by real-time RT-PCR. Additionally, we immunohistochemically investigated the expression levels of the major extracellular matrix (ECM) proteins in keloid spheroids transduced with dE1-RGD/GFP/DCN. Lower decorin expression was observed in the keloid region compared to adjacent normal tissues. After treatment with dE1-RGD/GFP/DCN, secreted TGF-β1 and EGFR protein expressions were decreased in TGF-β1-treated HDFs and KFs. Also, type I and III collagen mRNA levels were decreased, and the expression of MMP-1 and MMP-3 mRNA was strongly upregulated. In addition, the expression of type I and III collagen, fibronectin and elastin was significantly reduced in dE1-RGD/GFP/DCN-transduced keloid spheroids. These results support the utility of decorin-expressing adenovirus to reduce collagen synthesis in KFs and keloid spheroid, which may be highly beneficial in treating keloids.
Collapse
Affiliation(s)
- Won Jai Lee
- Department of Plastic and Reconstructive Surgery, College of Medicine, Institute for Human Tissue Restoration, Yonsei University, Seoul, Korea
| | - Hyo Min Ahn
- Department of Bioengineering, College of Engineering, Hanyang University, Seoul, Korea
| | - Hyun Roh
- Department of Plastic and Reconstructive Surgery, College of Medicine, Institute for Human Tissue Restoration, Yonsei University, Seoul, Korea
| | - Youjin Na
- Department of Bioengineering, College of Engineering, Hanyang University, Seoul, Korea
| | - Il-Kyu Choi
- Department of Bioengineering, College of Engineering, Hanyang University, Seoul, Korea
| | - Ju Hee Lee
- Department of Dermatology and Cutaneous Biology Research Institute, College of Medicine, Yonsei University, Seoul, Korea
| | - Yong Oock Kim
- Department of Plastic and Reconstructive Surgery, College of Medicine, Institute for Human Tissue Restoration, Yonsei University, Seoul, Korea
| | - Dae Hyun Lew
- Department of Plastic and Reconstructive Surgery, College of Medicine, Institute for Human Tissue Restoration, Yonsei University, Seoul, Korea
| | - Chae-Ok Yun
- Department of Bioengineering, College of Engineering, Hanyang University, Seoul, Korea
| |
Collapse
|
62
|
Nahar K, Absar S, Gupta N, Kotamraju VR, McMurtry IF, Oka M, Komatsu M, Nozik-Grayck E, Ahsan F. Peptide-coated liposomal fasudil enhances site specific vasodilation in pulmonary arterial hypertension. Mol Pharm 2014; 11:4374-84. [PMID: 25333706 PMCID: PMC4255731 DOI: 10.1021/mp500456k] [Citation(s) in RCA: 34] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/31/2023]
Abstract
![]()
This study sought to develop a liposomal
delivery system of fasudil—an
investigational drug for the treatment of pulmonary arterial hypertension
(PAH)—that will preferentially accumulate in the PAH lungs.
Liposomal fasudil was prepared by film-hydration method, and the drug
was encapsulated by active loading. The liposome surface was coated
with a targeting moiety, CARSKNKDC, a cyclic peptide;
the liposomes were characterized for size, polydispersity index, zeta
potential, and storage and nebulization stability. The in vitro drug
release profiles and uptake by TGF-β activated pulmonary arterial
smooth muscle cells (PASMC) and alveolar macrophages were evaluated.
The pharmacokinetics were monitored in male Sprague–Dawley
rats, and the pulmonary hemodynamics were studied in acute and chronic
PAH rats. The size, polydispersity index (PDI), and zeta potential
of the liposomes were 206–216 nm, 0.058–0.084, and −20–42.7
mV, respectively. The formulations showed minimal changes in structural
integrity when nebulized with a commercial microsprayer. The optimized
formulation was stable for >4 weeks when stored at 4 °C. Fasudil
was released in a continuous fashion over 120 h with a cumulative
release of 76%. Peptide-linked liposomes were taken up at a higher
degree by TGF-β activated PASMCs; but alveolar macrophages could
not engulf peptide-coated liposomes. The formulations did not injure
the lungs; the half-life of liposomal fasudil was 34-fold higher than
that of plain fasudil after intravenous administration. Peptide-linked
liposomal fasudil, as opposed to plain liposomes, reduced the mean
pulmonary arterial pressure by 35–40%, without influencing
the mean systemic arterial pressure. This study establishes that CAR-conjugated
inhalable liposomal fasudil offers favorable pharmacokinetics and
produces pulmonary vasculature specific dilatation.
Collapse
Affiliation(s)
- Kamrun Nahar
- Department of Pharmaceutical Sciences, School of Pharmacy, Texas Tech University Health Sciences Center , 1300 Coulter Street, Amarillo, Texas 79106, United States
| | | | | | | | | | | | | | | | | |
Collapse
|
63
|
Lorda-Diez CI, García-Porrero JA, Hurlé JM, Montero JA. Decorin gene expression in the differentiation of the skeletal connective tissues of the developing limb. Gene Expr Patterns 2014; 15:52-60. [DOI: 10.1016/j.gep.2014.04.003] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/31/2014] [Revised: 04/09/2014] [Accepted: 04/11/2014] [Indexed: 11/28/2022]
|
64
|
Rybinski B, Franco-Barraza J, Cukierman E. The wound healing, chronic fibrosis, and cancer progression triad. Physiol Genomics 2014; 46:223-44. [PMID: 24520152 PMCID: PMC4035661 DOI: 10.1152/physiolgenomics.00158.2013] [Citation(s) in RCA: 158] [Impact Index Per Article: 15.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/08/2013] [Accepted: 02/04/2014] [Indexed: 02/07/2023] Open
Abstract
For decades tumors have been recognized as "wounds that do not heal." Besides the commonalities that tumors and wounded tissues share, the process of wound healing also portrays similar characteristics with chronic fibrosis. In this review, we suggest a tight interrelationship, which is governed as a concurrence of cellular and microenvironmental reactivity among wound healing, chronic fibrosis, and cancer development/progression (i.e., the WHFC triad). It is clear that the same cell types, as well as soluble and matrix elements that drive wound healing (including regeneration) via distinct signaling pathways, also fuel chronic fibrosis and tumor progression. Hence, here we review the relationship between fibrosis and cancer through the lens of wound healing.
Collapse
Affiliation(s)
- Brad Rybinski
- Cancer Biology Program, Fox Chase Cancer Center/Temple Health, Philadelphia, Pennsylvania
| | | | | |
Collapse
|
65
|
Affiliation(s)
- Bethany Powell Gray
- Department of Internal Medicine and The Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, Texas 75390-8807, United States
| | - Kathlynn C. Brown
- Department of Internal Medicine and The Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, Texas 75390-8807, United States
| |
Collapse
|
66
|
Abstract
CONTEXT Aging changes the biology, healing capacity, and biomechanical function of tendons and ligaments and results in common clinical pathologies that present to orthopedic surgeons, primary care physicians, physical therapists, and athletic trainers. A better understanding of the age-related changes in these connective tissues will allow better patient care. EVIDENCE ACQUISITION The PubMed database was searched in December 2012 for English-language articles pertaining to age-related changes in tendons and ligaments. LEVEL OF EVIDENCE Level 5. RESULTS The mature athlete faces challenges associated with age-dependent changes in the rotator cuff, Achilles tendon, lateral humeral epicondylar tendons, quadriceps tendon, and patellar tendon. The anterior cruciate ligament and the medial collateral ligament are the most studied intra-articular and extra-articular ligaments, and both are associated with age-dependent changes. CONCLUSION Tendons and ligaments are highly arranged connective tissue structures that maintain joint motion and joint stability. These structures are subject to vascular and compositional changes with increasing age that alter their mechanotransduction, biology, healing capacity, and biomechanical function. Emerging research into the etiology of age-dependent changes will provide further information to help combat the age-related clinical complications associated with the injuries that occur to tendons and ligaments.
Collapse
|
67
|
Neill T, Torres A, Buraschi S, Owens RT, Hoek JB, Baffa R, Iozzo RV. Decorin induces mitophagy in breast carcinoma cells via peroxisome proliferator-activated receptor γ coactivator-1α (PGC-1α) and mitostatin. J Biol Chem 2014; 289:4952-68. [PMID: 24403067 DOI: 10.1074/jbc.m113.512566] [Citation(s) in RCA: 69] [Impact Index Per Article: 6.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/25/2022] Open
Abstract
Tumor cell mitochondria are key biosynthetic hubs that provide macromolecules for cancer progression and angiogenesis. Soluble decorin protein core, hereafter referred to as decorin, potently attenuated mitochondrial respiratory complexes and mitochondrial DNA (mtDNA) in MDA-MB-231 breast carcinoma cells. We found a rapid and dynamic interplay between peroxisome proliferator-activated receptor γ coactivator-1α (PGC-1α) and the decorin-induced tumor suppressor gene, mitostatin. This interaction stabilized mitostatin mRNA with concurrent accumulation of mitostatin protein. In contrast, siRNA-mediated abrogation of PGC-1α-blocked decorin-evoked stabilization of mitostatin. Mechanistically, PGC-1α bound MITOSTATIN mRNA to achieve rapid stabilization. These processes were orchestrated by the decorin/Met axis, as blocking the Met-tyrosine kinase or knockdown of Met abrogated these responses. Furthermore, depletion of mitostatin blocked decorin- or rapamycin-evoked mitophagy, increased vascular endothelial growth factor A (VEGFA) production, and compromised decorin-evoked VEGFA suppression. Collectively, our findings underscore the complexity of PGC-1α-mediated mitochondrial homeostasis and establish mitostatin as a key regulator of tumor cell mitophagy and angiostasis.
Collapse
Affiliation(s)
- Thomas Neill
- From the Department of Pathology, Anatomy, and Cell Biology and the Cancer Cell Biology and Signaling Program, Kimmel Cancer Center and
| | | | | | | | | | | | | |
Collapse
|
68
|
Toba M, Alzoubi A, O'Neill K, Abe K, Urakami T, Komatsu M, Alvarez D, Järvinen TAH, Mann D, Ruoslahti E, McMurtry IF, Oka M. A novel vascular homing peptide strategy to selectively enhance pulmonary drug efficacy in pulmonary arterial hypertension. THE AMERICAN JOURNAL OF PATHOLOGY 2014; 184:369-75. [PMID: 24401613 DOI: 10.1016/j.ajpath.2013.10.008] [Citation(s) in RCA: 40] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/05/2013] [Revised: 09/10/2013] [Accepted: 10/17/2013] [Indexed: 01/09/2023]
Abstract
A major limitation in the pharmacological treatment of pulmonary arterial hypertension (PAH) is the lack of pulmonary vascular selectivity. Recent studies have identified a tissue-penetrating homing peptide, CARSKNKDC (CAR), which specifically homes to hypertensive pulmonary arteries but not to normal pulmonary vessels or other tissues. Some tissue-penetrating vascular homing peptides have a unique ability to facilitate transport of co-administered drugs into the targeted cells/tissues without requiring physical conjugation of the drug to the peptide (bystander effect). We tested the hypothesis that co-administered CAR would selectively enhance the pulmonary vascular effects of i.v. vasodilators in Sugen5416/hypoxia/normoxia-exposed PAH rats. Systemically administered CAR was predominantly detected in cells of remodeled pulmonary arteries. Intravenously co-administered CAR enhanced pulmonary, but not systemic, effects of the vasodilators, fasudil and imatinib, in PAH rats. CAR increased lung tissue imatinib concentration in isolated PAH lungs without increasing pulmonary vascular permeability. Sublingual CAR was also effective in selectively enhancing the pulmonary vasodilation by imatinib and sildenafil. Our results suggest a new paradigm in the treatment of PAH, using an i.v./sublingual tissue-penetrating homing peptide to selectively augment pulmonary vascular effects of nonselective drugs without the potentially problematic conjugation process. CAR may be particularly useful as an add-on therapy to selectively enhance the pulmonary vascular efficacy of any ongoing drug treatment in patients with PAH.
Collapse
Affiliation(s)
- Michie Toba
- Departments of Pharmacology and Internal Medicine, Center for Lung Biology, University of South Alabama, College of Medicine, Mobile, Alabama
| | - Abdallah Alzoubi
- Departments of Pharmacology and Internal Medicine, Center for Lung Biology, University of South Alabama, College of Medicine, Mobile, Alabama
| | - Kealan O'Neill
- Departments of Pharmacology and Internal Medicine, Center for Lung Biology, University of South Alabama, College of Medicine, Mobile, Alabama
| | - Kohtaro Abe
- Departments of Pharmacology and Internal Medicine, Center for Lung Biology, University of South Alabama, College of Medicine, Mobile, Alabama
| | - Takeo Urakami
- Sanford-Burnham Medical Research Institute at Lake Nona, Orlando, Florida
| | - Masanobu Komatsu
- Sanford-Burnham Medical Research Institute at Lake Nona, Orlando, Florida
| | - Diego Alvarez
- Departments of Pharmacology and Internal Medicine, Center for Lung Biology, University of South Alabama, College of Medicine, Mobile, Alabama
| | - Tero A H Järvinen
- Medical School, University and University Hospital of Tampere, Tampere, Finland
| | - David Mann
- VBS Pharmaceuticals Division, Vascular BioSciences, Goleta, California
| | - Erkki Ruoslahti
- Cancer Center, Sanford-Burnham Medical Research Institute, La Jolla, California
| | - Ivan F McMurtry
- Departments of Pharmacology and Internal Medicine, Center for Lung Biology, University of South Alabama, College of Medicine, Mobile, Alabama
| | - Masahiko Oka
- Departments of Pharmacology and Internal Medicine, Center for Lung Biology, University of South Alabama, College of Medicine, Mobile, Alabama.
| |
Collapse
|
69
|
Abstract
Cutaneous wound healing assay is important to address many key questions including (1) migration ability of different cells; (2) communication between the different cell types such as keratinocytes, fibroblasts, and immune cells; (3) understanding the cell-autonomous and non-cell-autonomous function(s) of the different cells; and (4) gene regulation in healing processes. Wound healing studies can be used to test new treatment modalities, function of new drugs/compounds, and stem cell-based therapies on the different stages of healing and for accelerating wound healing in patients with compromised healing. In this chapter, we have described a simple step-by-step protocol to generate full-thickness cutaneous wounds in the dorsal skin of mice, followed by collecting the post-wounding biopsied materials on specific days for histological and immunohistochemical analyses and for RNA and protein extractions.
Collapse
Affiliation(s)
- Gitali Ganguli-Indra
- Department of Pharmaceutical Sciences, College of Pharmacy, Oregon State University, 1601 SW Jefferson str, Corvallis, OR, 97331, USA,
| |
Collapse
|
70
|
Nyström A, Velati D, Mittapalli VR, Fritsch A, Kern JS, Bruckner-Tuderman L. Collagen VII plays a dual role in wound healing. J Clin Invest 2013; 123:3498-509. [PMID: 23867500 PMCID: PMC3726167 DOI: 10.1172/jci68127] [Citation(s) in RCA: 147] [Impact Index Per Article: 13.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/03/2012] [Accepted: 05/09/2013] [Indexed: 01/01/2023] Open
Abstract
Although a host of intracellular signals is known to contribute to wound healing, the role of the cell microenvironment in tissue repair remains elusive. Here we employed 2 different mouse models of genetic skin fragility to assess the role of the basement membrane protein collagen VII (COL7A1) in wound healing. COL7A1 secures the attachment of the epidermis to the dermis, and its mutations cause a human skin fragility disorder coined recessive dystrophic epidermolysis bullosa (RDEB) that is associated with a constant wound burden. We show that COL7A1 is instrumental for skin wound closure by 2 interconnected mechanisms. First, COL7A1 was required for re-epithelialization through organization of laminin-332 at the dermal-epidermal junction. Its loss perturbs laminin-332 organization during wound healing, which in turn abrogates strictly polarized expression of integrin α6β4 in basal keratinocytes and negatively impacts the laminin-332/integrin α6β4 signaling axis guiding keratinocyte migration. Second, COL7A1 supported dermal fibroblast migration and regulates their cytokine production in the granulation tissue. These findings, which were validated in human wounds, identify COL7A1 as a critical player in physiological wound healing in humans and mice and may facilitate development of therapeutic strategies not only for RDEB, but also for other chronic wounds.
Collapse
Affiliation(s)
- Alexander Nyström
- Department of Dermatology, University Medical Center, Freiburg, Germany.
Freiburg Institute for Advanced Studies, School of Life Sciences — LifeNet, Freiburg, Germany
| | - Daniela Velati
- Department of Dermatology, University Medical Center, Freiburg, Germany.
Freiburg Institute for Advanced Studies, School of Life Sciences — LifeNet, Freiburg, Germany
| | - Venugopal R. Mittapalli
- Department of Dermatology, University Medical Center, Freiburg, Germany.
Freiburg Institute for Advanced Studies, School of Life Sciences — LifeNet, Freiburg, Germany
| | - Anja Fritsch
- Department of Dermatology, University Medical Center, Freiburg, Germany.
Freiburg Institute for Advanced Studies, School of Life Sciences — LifeNet, Freiburg, Germany
| | - Johannes S. Kern
- Department of Dermatology, University Medical Center, Freiburg, Germany.
Freiburg Institute for Advanced Studies, School of Life Sciences — LifeNet, Freiburg, Germany
| | - Leena Bruckner-Tuderman
- Department of Dermatology, University Medical Center, Freiburg, Germany.
Freiburg Institute for Advanced Studies, School of Life Sciences — LifeNet, Freiburg, Germany
| |
Collapse
|
71
|
Yanez CO, Morales AR, Yue X, Urakami T, Komatsu M, Järvinen TAH, Belfield KD. Deep vascular imaging in wounds by two-photon fluorescence microscopy. PLoS One 2013; 8:e67559. [PMID: 23844028 PMCID: PMC3699647 DOI: 10.1371/journal.pone.0067559] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/16/2013] [Accepted: 05/20/2013] [Indexed: 01/22/2023] Open
Abstract
Deep imaging within tissue (over 300 μm) at micrometer resolution has become possible with the advent of two-photon fluorescence microscopy (2PFM). The advantages of 2PFM have been used to interrogate endogenous and exogenous fluorophores in the skin. Herein, we employed the integrin (cell-adhesion proteins expressed by invading angiogenic blood vessels) targeting characteristics of a two-photon absorbing fluorescent probe to image new vasculature and fibroblasts up to ≈ 1600 μm within wound (neodermis)/granulation tissue in lesions made on the skin of mice. Reconstruction revealed three dimensional (3D) architecture of the vascular plexus forming at the regenerating wound tissue and the presence of a fibroblast bed surrounding the capillaries. Biologically crucial events, such as angiogenesis for wound healing, may be illustrated and analyzed in 3D on the whole organ level, providing novel tools for biomedical applications.
Collapse
Affiliation(s)
- Ciceron O. Yanez
- Department of Chemistry, University of Central Florida, Orlando, Florida, United States of America
| | - Alma R. Morales
- Department of Chemistry, University of Central Florida, Orlando, Florida, United States of America
| | - Xiling Yue
- Department of Chemistry, University of Central Florida, Orlando, Florida, United States of America
| | - Takeo Urakami
- Sanford-Burnham Medical Research Institute at Lake Nona, Orlando, Florida, United States of America
| | - Masanobu Komatsu
- Sanford-Burnham Medical Research Institute at Lake Nona, Orlando, Florida, United States of America
| | - Tero A. H. Järvinen
- Department of Orthopaedic Surgery, Tampere City Hospital and Medical School, University of Tampere, Tampere, Finland
| | - Kevin D. Belfield
- Department of Chemistry, University of Central Florida, Orlando, Florida, United States of America
- The College of Optics and Photonics, University of Central Florida, Orlando, Florida, United States of America
- * E-mail:
| |
Collapse
|
72
|
Finnson KW, McLean S, Di Guglielmo GM, Philip A. Dynamics of Transforming Growth Factor Beta Signaling in Wound Healing and Scarring. Adv Wound Care (New Rochelle) 2013; 2:195-214. [PMID: 24527343 PMCID: PMC3857355 DOI: 10.1089/wound.2013.0429] [Citation(s) in RCA: 201] [Impact Index Per Article: 18.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/22/2013] [Indexed: 12/12/2022] Open
Abstract
SIGNIFICANCE Wound healing is an intricate biological process in which the skin, or any other tissue, repairs itself after injury. Normal wound healing relies on the appropriate levels of cytokines and growth factors to ensure that cellular responses are mediated in a coordinated manner. Among the many growth factors studied in the context of wound healing, transforming growth factor beta (TGF-β) is thought to have the broadest spectrum of effects. RECENT ADVANCES Many of the molecular mechanisms underlying the TGF-β/Smad signaling pathway have been elucidated, and the role of TGF-β in wound healing has been well characterized. Targeting the TGF-β signaling pathway using therapeutic agents to improve wound healing and/or reduce scarring has been successful in pre-clinical studies. CRITICAL ISSUES Although TGF-β isoforms (β1, β2, β3) signal through the same cell surface receptors, they display distinct functions during wound healing in vivo through mechanisms that have not been fully elucidated. The challenge of translating preclinical studies targeting the TGF-β signaling pathway to a clinical setting may require more extensive preclinical research using animal models that more closely mimic wound healing and scarring in humans, and taking into account the spatial, temporal, and cell-type-specific aspects of TGF-β isoform expression and function. FUTURE DIRECTIONS Understanding the differences in TGF-β isoform signaling at the molecular level and identification of novel components of the TGF-β signaling pathway that critically regulate wound healing may lead to the discovery of potential therapeutic targets for treatment of impaired wound healing and pathological scarring.
Collapse
Affiliation(s)
- Kenneth W. Finnson
- Division of Plastic Surgery, Department of Surgery, Montreal General Hospital, McGill University, Montreal, Canada
| | - Sarah McLean
- Department of Physiology and Pharmacology, Western University, London, Canada
| | | | - Anie Philip
- Division of Plastic Surgery, Department of Surgery, Montreal General Hospital, McGill University, Montreal, Canada
| |
Collapse
|
73
|
Finnson KW, Arany PR, Philip A. Transforming Growth Factor Beta Signaling in Cutaneous Wound Healing: Lessons Learned from Animal Studies. Adv Wound Care (New Rochelle) 2013; 2:225-237. [PMID: 24761336 DOI: 10.1089/wound.2012.0419] [Citation(s) in RCA: 75] [Impact Index Per Article: 6.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/14/2013] [Indexed: 12/11/2022] Open
Abstract
SIGNIFICANCE Wound healing is a complex physiological process involving a multitude of growth factors, among which transforming growth factor beta (TGF-β) has the broadest spectrum of effects. Animal studies have provided key information on the mechanisms of TGF-β action in wound healing and have guided the development of therapeutic strategies targeting the TGF-β pathway to improve wound healing and scarring outcome. RECENT ADVANCES Development of tissue-specific expression systems for overexpression or knockout of TGF-β signaling pathway components has led to novel insight into the role of TGF-β signaling in wound healing. This work has also identified molecules that might serve as molecular targets for the treatment of pathological skin conditions such as chronic wounds and excessive scarring (fibrosis). CRITICAL ISSUES Many of the mouse models with genetic alterations in the TGF-β signaling pathway develop an underlying skin abnormality, which may pose some limitations on the interpretation of wound-healing results obtained in these animals. Also, TGF-β's pleiotropic effects on many cell types throughout all phases of wound healing present a challenge in designing specific strategies for targeting the TGF-β signaling pathway to promote wound healing or reduce scarring. FUTURE DIRECTIONS Further characterization of TGF-β signaling pathway components using inducible tissue-specific overexpression or knockout technology will be needed to corroborate results obtained in mouse models that display a skin phenotype, and to better understand the role of TGF-β signaling during distinct phases of the wound-healing process. Such studies will also provide a better understanding of how TGF-β mediates its autocrine, paracrine, and double paracrine effects on cellular responses in vivo during wound healing.
Collapse
Affiliation(s)
- Kenneth W. Finnson
- Division of Plastic Surgery, Department of Surgery, McGill University, Montreal General Hospital, Montreal, Canada
| | - Praveen R. Arany
- Cell Regulation and Control Unit, Oral and Pharyngeal Cancer Branch, National Institute of Dental and Craniofacial Research, National Institutes of Health, Bethesda, Maryland
| | - Anie Philip
- Division of Plastic Surgery, Department of Surgery, McGill University, Montreal General Hospital, Montreal, Canada
| |
Collapse
|
74
|
Bengel FM, George RT, Schuleri KH, Lardo AC, Wollert KC. Image-guided therapies for myocardial repair: concepts and practical implementation. Eur Heart J Cardiovasc Imaging 2013; 14:741-51. [PMID: 23720377 DOI: 10.1093/ehjci/jet038] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/15/2022] Open
Abstract
Cell- and molecule-based therapeutic strategies to support wound healing and regeneration after myocardial infarction (MI) are under development. These emerging therapies aim at sustained preservation of ventricular function by enhancing tissue repair after myocardial ischaemia and reperfusion. Such therapies will benefit from guidance with regard to timing, regional targeting, suitable candidate selection, and effectiveness monitoring. Such guidance is effectively obtained by non-invasive tomographic imaging. Infarct size, tissue characteristics, muscle mass, and chamber geometry can be determined by magnetic resonance imaging and computed tomography. Radionuclide imaging can be used for the tracking of therapeutic agents and for the interrogation of molecular mechanisms such as inflammation, angiogenesis, and extracellular matrix activation. This review article portrays the hypothesis that an integrated approach with an early implementation of structural and molecular tomographic imaging in the development of novel therapies will provide a framework for achieving the goal of improved tissue repair after MI.
Collapse
Affiliation(s)
- Frank M Bengel
- Department of Nuclear Medicine, Hannover Medical School, Carl-Neuberg-Str. 1, Hannover 30625, Germany.
| | | | | | | | | |
Collapse
|
75
|
Järvinen TA, Ruoslahti E. Targeted Antiscarring Therapy for Tissue Injuries. Adv Wound Care (New Rochelle) 2013; 2:50-54. [PMID: 24527325 DOI: 10.1089/wound.2011.0299] [Citation(s) in RCA: 31] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/13/2011] [Indexed: 11/12/2022] Open
Abstract
SIGNIFICANCE The healing of injuries, such as those caused by ischemia (myocardial infarction, stroke), trauma, surgery, and inflammation, tends to happen through undesirable and harmful scarring. Current options in reducing scar formation are largely limited to local intervention in accessible tissues. RECENT ADVANCES We have designed a systemically administered, injury-targeted decorin for scar prevention. The delivery of decorin to injured tissues is achieved by fusing recombinant decorin to a 9-amino acid peptide, CARSKNKDC (CAR), which specifically recognizes the vessels in injured tissues and extravasates into the tissue, delivering decorin with it. CRITICAL ISSUES Decorin is known to prevent tissue fibrosis and promote tissue regeneration. This activity of decorin is based on inhibition of TGF-β and some other regulatory activities. In addition to serving as a delivery vehicle, the CAR component endowed decorin with much stronger neutralizing activity against TGF-β1 in vitro than is obtained with nontargeted decorin. The CAR-decorin fusion protein promoted wound healing in a mouse skin wound model and suppressed scar formation at doses at which nontargeted decorin was inactive. These results show that selective targeting enhances specificity and potency of an antiscarring compound. FUTURE DIRECTIONS Targeted decorin provides a new, systemic option for the treatment of scarring and fibrotic diseases.
Collapse
Affiliation(s)
- Tero A.H. Järvinen
- Vascular Mapping Laboratory, Center for Nanomedicine, Sanford-Burnham Medical Research Institute at UCSB, University of California, Santa Barbara, California
- Cancer Research Center, Sanford-Burnham Medical Research Institute, La Jolla, California
- Department of Orthopaedic Surgery, University of Tampere and Tampere City Hospital, Tampere, Finland
| | - Erkki Ruoslahti
- Vascular Mapping Laboratory, Center for Nanomedicine, Sanford-Burnham Medical Research Institute at UCSB, University of California, Santa Barbara, California
- Cancer Research Center, Sanford-Burnham Medical Research Institute, La Jolla, California
| |
Collapse
|
76
|
Maciejewski CC, Honardoust D, Tredget EE, Metcalfe PD. Differential expression of class I small leucine-rich proteoglycans in an animal model of partial bladder outlet obstruction. J Urol 2012; 188:1543-8. [PMID: 22910252 DOI: 10.1016/j.juro.2012.03.045] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/28/2011] [Indexed: 11/29/2022]
Abstract
PURPOSE Partial bladder outlet obstruction has been shown in a rat model to progress from inflammation to hypertrophy to fibrosis. Small leucine-rich proteoglycans are extracellular matrix components associated with collagen fibrillogenesis and resultant scar formation. Two such critical small leucine-rich proteoglycans are decorin and biglycan. We hypothesized that in keeping with other scar models, decorin would be down-regulated and biglycan would be up-regulated with the onset of fibrosis compared to sham. MATERIALS AND METHODS We challenged our hypothesis with female Fisher rats that underwent ligation of the bladder neck or sham surgery. Animals were sacrificed at 4, 8 and 12 weeks, and bladders were harvested. Frozen sections were stained for immunofluorescence for decorin and biglycan. mRNA expression for decorin and biglycan was analyzed using quantitative reverse transcriptase polymerase chain reaction. RESULTS All rats survived to specified experimental end points in good health. Immunofluorescent stains showed progressive down-regulation of decorin and up-regulation of biglycan during the 12-week course by 0.36 and 1.82-fold, respectively (p = 0.02 and p = 0.02), compared to shams. Quantitative real-time reverse transcriptase polymerase chain reaction confirmed these findings in 12-week specimens, showing a down-regulation of decorin by a factor of 0.45 (p = 0.02) and up-regulation of biglycan by a factor of 2.04-fold (p = 0.08). CONCLUSIONS We present the first identification to our knowledge of small leucine-rich proteoglycans in normal and abnormal bladder tissue, and their differential expression in the process of bladder fibrosis, consistent with experimental findings in other anatomical sites. Further investigation into small leucine-rich proteoglycan expression and regulation may allow for the development of new antifibrotic therapeutics.
Collapse
Affiliation(s)
- Conrad C Maciejewski
- Division of Urology, Department of Surgery, University of Alberta, Edmonton, Alberta, Canada.
| | | | | | | |
Collapse
|
77
|
Affiliation(s)
- Pramod B. Voleti
- McKay Orthopaedic Research Laboratory, Department of Orthopaedic Surgery, University of Pennsylvania, Philadelphia, Pennsylvania 19104-6081;
| | - Mark R. Buckley
- McKay Orthopaedic Research Laboratory, Department of Orthopaedic Surgery, University of Pennsylvania, Philadelphia, Pennsylvania 19104-6081;
| | - Louis J. Soslowsky
- McKay Orthopaedic Research Laboratory, Department of Orthopaedic Surgery, University of Pennsylvania, Philadelphia, Pennsylvania 19104-6081;
| |
Collapse
|
78
|
Abstract
Selective delivery of drugs and biotherapeutics to the site of disease (synaphic targeting) has a number of advantages. First, the enhanced accumulation of the therapeutic compound at the target tissue increases drug efficacy without increasing side effects. Alternatively, the dose of the drug can be lowered to reduce the side effects. On the practical level, when a drug is difficult or expensive to make, being able to lower the dose may be the key to commercial viability. Certain targeting systems can change the distribution of the drug in a beneficial way. Examples include wider distribution and deeper penetration of the drug in the target tissue, active intracellular targeting when desirable, and even targeting to a particular subcellular organelle. In this chapter, we illustrate these principles by describing the development of a targeting system for an antifibrotic biotherapeutic, decorin. The system is based on vascular homing peptide (sequence: CARSKNKDC; referred to as CAR) that specifically recognizes angiogenic blood vessels in injured (regenerating) and inflammatory tissues and can deliver a payload to such tissues with high selectivity. So far, the CAR-targeted decorin has been shown to promote tissue repair with reduced scarring in a skin wound model, but this biotherapeutic can potentially be used in other injuries and in various fibrotic diseases.
Collapse
Affiliation(s)
- Tero A H Järvinen
- Vascular Mapping Laboratory, Center for Nanomedicine, Sanford-Burnham Medical Research Institute at UCSB, University of California, Santa Barbara, California, USA
| |
Collapse
|
79
|
Ferrini MG, Moon J, Rivera S, Rajfer J, Gonzalez-Cadavid NF. Amelioration of diabetes-induced cavernosal fibrosis by antioxidant and anti-transforming growth factor-β1 therapies in inducible nitric oxide synthase-deficient mice. BJU Int 2011; 109:586-93. [PMID: 21851542 DOI: 10.1111/j.1464-410x.2011.10397.x] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
Abstract
OBJECTIVE • To investigate whether sustained long-term separate treatments of diabetic inducible nitric oxide synthase knockout (iNOSKo) mice with allopurinol, an antioxidant inhibiting xanthine oxidoreductase, decorin, a transforming growth factor-β1 (TGFβ1) -binding antagonist, and molsidomine, a long-life nitric oxide donor, prevent the processes of diabetes-induced cavernosal fibrosis. MATERIALS AND METHODS • Eight week old male iNOS knock out (iNOSKo) mice were made diabetic by injecting 150 mg/kg B.W Streptozotocin (1P) with were either left untreated or treated with the oral antioxidant allopurinol (40 mg/kg/day), or decoin (50 mg, 1P, twice), as an anti-TGFβ1 agent (n = 8/group). • Glycemia and oxidative stress markers were determined in blood and urine. • Paraffin-embedded tissue sections from the penile shaft were subjected to Masson trichrome staining for the smooth muscle (smc)/collagen ratio, and imunostaining for smc content, profibrotic factors, oxidative stress, cell replication and cell death markers followed by quantitative image analysis. RESULTS • Eight-week treatment with either allopurinol or decorin counteracted the decrease in smooth muscle cells and the increase in apoptosis and local oxidative stress within the corpora tissue. • Decorin but not allopurinol increased the smooth muscle cell/collagen ratio, whereas allopurinol but not decorin inhibited systemic oxidative stress. • Molsidomine was effective in reducing both local and systemic oxidative stress, but did not prevent corporal fibrosis. CONCLUSION • Both allopurinol and decorin appear as promising approaches either as a single or a combined pharmacological modality for protecting the diabetic corpora from undergoing apoptosis and fibrosis although their functional effects still need to be defined.
Collapse
Affiliation(s)
- Monica G Ferrini
- Department of Internal Medicine, Charles R. Drew University Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
| | | | | | | | | |
Collapse
|
80
|
Urakami T, Järvinen TAH, Toba M, Sawada J, Ambalavanan N, Mann D, McMurtry I, Oka M, Ruoslahti E, Komatsu M. Peptide-directed highly selective targeting of pulmonary arterial hypertension. THE AMERICAN JOURNAL OF PATHOLOGY 2011; 178:2489-95. [PMID: 21549345 DOI: 10.1016/j.ajpath.2011.02.032] [Citation(s) in RCA: 38] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/01/2010] [Revised: 01/19/2011] [Accepted: 02/28/2011] [Indexed: 10/18/2022]
Abstract
Pulmonary arterial hypertension (PAH) is a disorder of the pulmonary vasculature associated with elevated pulmonary vascular resistance. Despite recent advances in the treatment of PAH, with eight approved clinical therapies and additional therapies undergoing clinical trials, PAH remains a serious life-threatening condition. The lack of pulmonary vascular selectivity and associated systemic adverse effects of these therapies remain the main obstacles to successful treatment. Peptide-mediated drug delivery that specifically targets the vasculature of PAH lungs may offer a solution to the lack of drug selectivity. Herein, we show highly selective targeting of rat PAH lesions by a novel cyclic peptide, CARSKNKDC (CAR). Intravenous administration of CAR peptide resulted in intense accumulation of the peptide in monocrotaline-induced and SU5416/hypoxia-induced hypertensive lungs but not in healthy lungs or other organs of PAH rats. CAR homed to all layers of remodeled pulmonary arteries, ie, endothelium, neointima, medial smooth muscle, and adventitia, in the hypertensive lungs. CAR also homed to capillary vessels and accumulated in the interstitial space of the PAH lungs, manifesting its extravasation activity. These results demonstrated the remarkable ability of CAR to selectively target PAH lung vasculature and effectively penetrate and spread throughout the diseased lung tissue. These results suggest the clinical utility of CAR in the targeted delivery of therapeutic compounds and imaging probes to PAH lungs.
Collapse
Affiliation(s)
- Takeo Urakami
- Sanford-Burnham Medical Research Institute (formerly the Burnham Institute for Medical Research) at Lake Nona, Orlando, Florida, USA
| | | | | | | | | | | | | | | | | | | |
Collapse
|
81
|
Abstract
Wound healing is a complex biological process that affects multiple tissue types. Wounds in the oral cavity are particularly challenging given the variety of tissue types that exist in close proximity to one another. The goal of regenerative medicine is to facilitate the rapid replacement of lost or damaged tissue with tissue that is functional, and physiologically similar to what previously existed. This review provides a general overview of wound healing and regenerative medicine, focusing specifically on how recent advances in the fields of stem cell biology, tissue engineering, and oral disease could translate into improved clinical outcomes.
Collapse
Affiliation(s)
- A Nauta
- Hagey Laboratory for Pediatric and Regenerative Medicine, Division of Plastic and Reconstructive Surgery, Department of Surgery, Institute of Stem Cell Biology and Regenerative Medicine, Stanford University School of Medicine, Stanford, CA, USA
| | | | | |
Collapse
|